Zynerba Pharmaceuticals Achieves Target Enrollment in Exploratory …

DEVON, Pa., June 08, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today announced that it has met its enrollment target of 16 patients in its Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in children with Fragile X syndrome (FXS). ZYN002 CBD gel is the first and only patent-protected, synthetic CBD that is formulated as a permeation-enhanced gel for transdermal delivery, and was awarded orphan drug designation by the U.S. Food and Drug Administration for the treatment for FXS.

Patients between the ages of 6 and 17 years with Fragile X syndrome have been enrolled in the exploratory FAB-C trial, which is designed to evaluate the safety and efficacy of ZYN002 CBD gel

... read more at: https://globenewswire.com/news-release/2017/06/08/1010310/0/en/Zynerba-Pharmaceuticals-Achieves-Target-Enrollment-in-Exploratory-Phase-2-Trial-of-ZYN002-in-Fragile-X-Syndrome.html